| Pegasys (pegylated interferon α -2a) / Roche |
NCT02604823: A Study of Peginterferon Alfa-2a (Pegasys) in Participants With Hepatitis B E-Antigen (HBeAg)-Positive Chronic Hepatitis B Virus (HBV) |
|
|
| Completed | 4 | 307 | RoW | Peginterferon alfa-2a, Pegasys | Hoffmann-La Roche | Hepatitis B, Chronic | 11/05 | 11/05 | | |
NCT02570191: A Study of PEGASYS (Peginterferon Alfa-2a [40KD]) in Patients With Hepatitis B e Antigen (HBeAg)-Negative Chronic Hepatitis B Virus (HBV) |
|
|
| Completed | 4 | 60 | Europe | Peginterferon alfa-2a, Pegasys | Hoffmann-La Roche | Hepatitis B, Chronic | 02/07 | 02/07 | | |
NCT00226382: Treatment With Peginterferon Alfa-2a (40 KD) of Chronic Hepatitis B Patients, Who Have Failed Anti-viral Treatment |
|
|
| Completed | 4 | 50 | RoW | Pegylated Interferon-alfa-2a | Chinese University of Hong Kong, Hoffmann-La Roche | Chronic Hepatitis B | 04/08 | 04/08 | | |
NCT01519921: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B. |
|
|
| Completed | 4 | 150 | RoW | peginterferon alfa-2a [Pegasys] | Hoffmann-La Roche | Hepatitis B, Chronic | 06/08 | 06/08 | | |
NCT02791269: A Study of Peginterferon Alfa-2a in Participants With Chronic Hepatitis B Virus (HBV) in an Expanded Access Program |
|
|
| Completed | 4 | 24 | RoW | Peginterferon alfa-2a, Pegasys | Hoffmann-La Roche | Hepatitis B, Chronic | 07/08 | 07/08 | | |
NCT00291616: Efficacy Study of Thymosin alpha1 & Pegylated Interferon-alpha2a to Treat Chronic Hepatitis B |
|
|
| Completed | 4 | 52 | RoW | Pegylated Interferon-alpha2a, Thymosin alpha1 & Pegylated Interferon-alpha2a | Seoul National University Hospital, Roche Pharma AG, SciClone Pharmaceuticals | Chronic Hepatitis B | 08/08 | 08/08 | | |
NCT02598063: A Study to Evaluate Efficacy and Safety of Peginterferon Alfa-2a (Pegasys) and Adeforvir Dipivoxil (ADV) in Participants With Lamivudine-Resistant Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B |
|
|
| Completed | 4 | 255 | RoW | Adefovir dipivoxil, Lamivudine, Peginterferon alfa-2a, Pegasys | Hoffmann-La Roche | Hepatitis B, Chronic | 04/09 | 04/09 | | |
NCT01787279: An Expanded Access Study of Pegasys (Peginterferon Alfa-2a) in Patients With HBeAg-Negative Chronic Hepatitis B |
|
|
| Completed | 4 | 59 | RoW | Peginterferon alfa-2a [Pegasys] | Hoffmann-La Roche | Hepatitis B, Chronic | 05/09 | 05/09 | | |
NCT00487747: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Chronic Hepatitis B. |
|
|
| Completed | 4 | 18 | RoW | peginterferon alfa-2a [Pegasys] | Hoffmann-La Roche | Hepatitis B, Chronic | 10/09 | 10/09 | | |
NCT00614471: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Entecavir in Treatment-Naive Patients With HBeAg-Positive Chronic Hepatitis B. |
|
|
| Completed | 4 | 219 | RoW | Entecavir, peginterferon alfa-2a [Pegasys] | Hoffmann-La Roche | Hepatitis B, Chronic | 10/09 | 10/09 | | |
NCT00436163 / 2006-005370-49: A Study of Peginterferon Alfa-2a (40KD) (PEGASYS®) in Participants With Hepatitis B Envelope Antigen (HBeAg) - Positive Chronic Hepatitis B |
|
|
| Completed | 4 | 39 | Europe | Peginterferon alfa-2a, Pegasys® | Hoffmann-La Roche | Hepatitis B, Chronic | 05/10 | 05/10 | | |
NCT00435825 / 2006-000870-63: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Hepatitis Be Antigen (HBeAg) Positive Chronic Hepatitis B (CHB). |
|
|
| Completed | 4 | 551 | US, Europe, RoW | peginterferon alfa-2a [Pegasys] | Hoffmann-La Roche | Hepatitis B, Chronic | 12/10 | 12/10 | | |
NCT00940485: A Study of Combination or Sequential Treatment With PEGASYS (Peginterferon Alfa-2a) and Entecavir in Patients With HBeAg Positive Chronic Hepatitis B |
|
|
| Completed | 4 | 200 | RoW | entecavir, peginterferon alfa-2a [Pegasys] | Hoffmann-La Roche | Hepatitis B, Chronic | 12/11 | 12/11 | | |
NCT01086085: A Study of Peginterferon Alfa-2a [PEGASYS] in Patients With Chronic Hepatitis B Who Are HBeAg Positive |
|
|
| Completed | 4 | 265 | RoW | Adefovir, peginterferon alfa-2a [PEGASYS] | Hoffmann-La Roche, Major Science and Technology Special Project of China Eleventh Five-year | Hepatitis B, Chronic | 03/13 | 03/13 | | |
NCT01277601 / 2010-024586-45: Efficacy & Safety of Tenofovir Disoproxil Fumarate (TDF) Plus Peginterferon α-2a (Peg-IFN) Versus TDF or Peg-IFN Monotherapy in Chronic Hepatitis B |
|
|
| Completed | 4 | 751 | US, Canada, Europe, RoW | TDF, Viread®, Peg-IFN, Pegasys® | Gilead Sciences | Chronic Hepatitis B | 08/14 | 07/15 | | |
NCT00922207: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Adefovir or Entecavir in Patients With HBeAg-Positive Chronic Hepatitis B |
|
|
| Completed | 4 | 280 | RoW | Adefovir, Entecavir, Placebo, peginterferon alfa-2a [Pegasys] | Hoffmann-La Roche | Hepatitis B, Chronic | 09/14 | 09/14 | | |
NCT00927082: A Follow-Up Study to WV19432, to Evaluate Long Term Post-Treatment Effects of PEGASYS (Peginterferon Alfa-2a(40KD))in Patients With HBeAg Positive Chronic Hepatitis B |
|
|
| Completed | 4 | 383 | RoW | peginterferon alfa-2a [Pegasys] | Hoffmann-La Roche | Hepatitis B, Chronic | 11/14 | 11/14 | | |
NCT01179594: A Study of 48 Versus 96 Weeks of Peginterferon Alfa-2a [Pegasys] Treatment, With or Without Entecavir, in Patients With Chronic Hepatitis B. |
|
|
| Withdrawn | 4 | 0 | NA | entecavir, peginterferon alfa-2a [Pegasys], placebo | Hoffmann-La Roche | Hepatitis B, Chronic | 11/14 | 11/14 | | |
